Bispecific Antibody

Technology

Last mentioned: Mar 20, 2026

Timeline

  1. IND Filing

    Potential window for Investigational New Drug application with the FDA.

  2. Preclinical Initiation

    Start of IND-enabling studies and toxicology assessments.

  3. Candidate Selection

    Expected naming of the lead development candidate for the program.

  4. Strategy Announcement

    iBio outlines bispecific approach for PH-HFpEF.

Stories mentioning Bispecific Antibody 1

clinical-trial Bullish

iBio Targets Q3 for Lead Bispecific Candidate in PH-HFpEF Treatment

iBio is advancing its bispecific antibody strategy to address Pulmonary Hypertension associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), a major unmet medical need. The company expects to select a formal development candidate by the third quarter of 2026, signaling a transition from discovery to preclinical development for its lead cardiovascular program.

2 sources